A Phase 1 interventional study of CSB-001 Ophthalmic Solution 0.1% in Corneal Scar, sponsored by Claris Biotherapeutics, Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-07.
Sponsored by Claris Biotherapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Corneal Injuries with a site in United States — 4 open to participants now, 4 under way, 1 of them phase 3. Corneal Injuries · United States.
Among the 15 studies in Corneal Injuries with a site in United States, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 1, and was the 13th registered.
38 studies on the registry are indexed under Corneal Injuries; 8 are open to participants now.
Browse Corneal Injuries studies →4 of the 15 studies in Corneal Injuries with a site in United States are open now. Recruiting first, the newest first:
Krystal Biotech, Inc. · Sites in United States
Ages 6 mo+
Krystal Biotech, Inc. · Sites in United States
Ages 6 mo+
Boston Children's Hospital · Sites in United States
Ages 8–35 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Corneal Injuries studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 2
First in 2004; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 36 across 28 interventional studies indexed under Corneal Injuries.
Median enrollment 22 across the 12 interventional studies, 40 across the 3 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 15 have an industry lead sponsor. The 10 most frequent:
Claris Biotherapeutics, Inc. is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Claris Biotherapeutics, Inc. has 1 study filed under Corneal Injuries — fewer than ten, so there is no comparison to draw.
3 of the studies in Corneal Injuries with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07016750Phase 3Krystal Biotech, Inc.A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa | 2026-12 |
| NCT06257355Claris Biotherapeutics, Inc.Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects With Corneal Scars | 2027-06-30 |
| NCT04439552Boston Children's HospitalfMRI and IVCM Cornea Microscopy of CXL in Keratoconus | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies in Corneal Injuries with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will enroll subjects with recently formed corneal scars that resulted from a corneal insult presenting and diagnosed within the past approximately 30 days and not less than approximately 7 days. All subjects will be assigned to CSB-001 investigational treatment on Day 1. All subjects will dose with CSB-001 four times daily or three times daily starting on Day 1 and continue until Day 14. Subjects with a resolved scar at Day 7 will discontinue dosing and return to the clinic on Day 14. Subjects will return on Days 21, 28, 56, and Month 3 for safety and efficacy assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other inclusion/exclusion criteria apply.
One drop CSB-001 four times daily for 14 days in the study eye
Biological: CSB-001 Ophthalmic Solution 0.1%
One drop CSB-001 three times daily for 14 days in the study eye
Biological: CSB-001 Ophthalmic Solution 0.1%
CSB-001: human recombinant dHGF (5-amino acid deleted hepatocyte growth factor)
Safety as Assessed by Adverse Event Reporting
Incidence of ocular and systemic adverse events
Time frame: Day 1 through Day 56
Safety as Assessed by Slit-lamp Biomicroscopy
Change from baseline in staining using NEI scale (0 = absent to 3 = severe for 5 areas of the cornea) with Grade 0 (no staining) to maximum of Grade 15
Time frame: Screening through Day 56
Safety as Assessed by Best-Corrected Distance Visual Acuity
Change from baseline using the Early Treatment Diabetic Retinopathy Study (EDTRS) visual acuity chart
Time frame: Screening through Day 56
Efficacy as Assessed by Area of Corneal Scar
Area of corneal scar as measured by slit lamp and anterior segment optical coherence tomography (AS-OCT) imaging
Time frame: Screening through Day 56
Efficacy as Assessed by Maximum Depth of Cornea Scar
Depth measured with AS-OCT imaging
Time frame: Screening through Day 56
Efficacy as Assessed by Volume of Scar
Volume measured with AS-OCT imaging
Time frame: Screening through Day 56
Efficacy as Assessed by Density of Scar
Density based on AS-OCT and Pentacam imaging
Time frame: Screening through Day 56
Efficacy as Assessed by Contrast Sensitivity
Contrast sensitivity measured using Pelli-Robson chart
Time frame: Screening through Day 56
Efficacy as Assessed by Distance Visual Acuity
Visual acuity measured using the EDTRS visual acuity chart
Time frame: Screening through Day 56
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Jun 2027, 40 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: CSB-001
Claris Biotherapeutics, Inc.